Strontium

Summary

Strontium (CHEMBL1201359) is an approved small molecule; indicated across 2 conditions including osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 4
• Chemistry: 87.62 Da · Sr

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201359
Name	Strontium
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	5359327
ChEBI	CHEBI:33324
Molecular formula	Sr
Molecular weight	87.62
InChIKey	CIOAGBVUUVVLOB-UHFFFAOYSA-N

SMILES: [Sr]

IUPAC name: strontium

Also known as: Strontium, STRONTIUM

Patent coverage: 8,366 distinct patent families (17,781 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoporosis	2	MONDO:0005298	EFO:0003882

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
Not specified	2
PHASE2/PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02128633	PHASE2/PHASE3	COMPLETED	Effectiveness of a Homecare Dentin Hypersensitivity Gel
NCT00081159	PHASE2	COMPLETED	Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
NCT01595815	Not specified	COMPLETED	Successful Pregnancy and Delivery After AOA
NCT03761979	Not specified	COMPLETED	Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).